Pharmaceutical manufacturers of Active pharmaceutical ingredients

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Dr. Reddy’s Laboratories Ltd. functions as an integrated pharmaceutical firm, dedicated to supplying cost-effective and innovative medications to promote healthier lifestyles. With a focus on Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products, Dr. Reddy’s delivers a range of products and services such as APIs, customized pharmaceutical services, generics, biosimilars, and distinct formulations. The primary therapeutic areas of concentration encompass gastro-intestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s has a presence in various global markets, with significant engagements in the USA, Europe, India, Russia, and other CIS nations.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

Formosa Laboratories serves customers globally as a leading supplier of active pharmaceutical ingredients (APIs). They offer a comprehensive range of CDMO services, including the development and production of APIs, ADCs, and cytotoxic and non-cytotoxic injectables using aseptic liquid filling and lyophilization processes. Formosa Laboratories is equipped to provide full-service GMP manufacturing for drug substances, ADCs, and drug products through its API and injectable facilities, which are designed to accommodate small molecules and more.

Established in 1953, Biological E Limited is a prominent producer of human vaccines including Tetanus, DT, DTP, Td HepatitisB, DTP-HepB-Hib Pentavalent, Hib, IPV, Japanese encephalitis, Measles, and Rubella, as well as Tetanus Antitoxin and Snake Antivenin. The company has obtained WHO prequalification for Tetanus, DTPHepBHib, JE, DTP, and Td. Additionally, they produce APIs such as Noscapine Base and HCL (Alkaloids) and Heparin Sodium, along with pipeline injectables like Heparin Inj, LMWH Enoxaparin, Dalteparin, Fosaprepitant, Daptomycin, Risperidone, and Paliperidone Palmitate.

The IMCD Group stands as a dominant force worldwide in the marketing, sales, and distribution of specialized chemicals and components. Its outcome-oriented experts offer tailored solutions to suppliers and clients throughout EMEA, Americas, and Asia-Pacific, delivering extensive product portfolios encompassing household, industrial and institutional maintenance, personal care, food and nutrition, pharmaceuticals, lubricants and energy, coatings and construction, advanced materials, and synthesis. In 2020, the IMCD Group achieved revenues of EUR 2,775 million, employing almost 3,300 individuals across more than 50 nations. IMCD's committed team of technical and business professionals collaborates closely to customize top-notch solutions and deliver expertise-based value to approximately 50,000 clients and a varied set of leading suppliers. IMCD shares can be traded on Euronext, Amsterdam (IMCD).

Aastrid International is recognized as a company with ISO 9001:2015 certification and is acknowledged as a star export house by the government of India. This esteemed company has established offices in India, China, and the UAE. Aastrid's export portfolio includes APIs, Intermediates, pellets, and excipients, which are distributed to over 45 countries worldwide. Aastrid is renowned for being a trustworthy and reliable partner in the supply chain.